OakChart

Redhill Biopharma Ltd ADR

RDHLHealthcare·Drug Manufacturers - Specialty & Generic·Israel·Nano·NASD·Nov 11 • 4:00 PM ET

0.3660-0.0091 (-2.43%)
2026-11-12 06:16 CET
Market cap
3.25 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-6.14 USD m
Free cash flow, TTM
-4.61 USD m
EPS diluted, TTM
-1.01
P/E
-
Compare

Price

RDHL against its 20, 50 and 200-day averages
2050200
0.501.001.5052.0M104.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RDHLclose 0.3720-day 0.4350-day 0.51200-day 0.770.3752w high

77.1% under the 52-week high of 1.60 on 31 Aug 2026. 52-week low 0.37 on 11 Nov 2026. Last 15 sessions, 28.7% high to low

Volume 0.02× normal · the line is the 50-bar volume average

Profile

RDHL
52-week range, 0% of the way up
0.381.60

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Employees13
IPOJan 07, 2013
Beta4.86
ATR, 14d0.04
Rel volume0.02
Short float0.77%
Insider own11.09%
Inst own3.49%

Snapshot

6 groups

Valuation

Index-
Market Cap3.25M
Enterprise Value-0.84M
Income-
Sales-
Book/sh-0.18
Cash/sh0.58
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees13
IPOJan 07, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C0.63
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.34
Current Ratio0.34
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y95.56% 86.32%
Sales past 3/5Y-83.27% -66.14%
EPS Y/Y TTM94.65%
Sales Y/Y TTM-
EPS Q/Q102.33%
Sales Q/Q-90.20%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own11.09%
Insider Trans-96.65%
Inst Own3.49%
Inst Trans0.32%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-15.41%
SMA50-28.46%
SMA200-52.70%
Trades-

Technical

Shs Outstand8.89M
Shs Float7.90M
Short Float0.77%
Short Ratio0.03
Short Interest0.06M
52W High1.60 -77.13%
52W Low0.38 -2.40%
Volatility7.91% 9.40%
ATR (14)0.04
RSI (14)34.60
Beta4.86
Rel Volume0.02
Avg Volume2.05M
Volume34,242

Performance

Perf Week-13.27%
Perf Month-28.93%
Perf Quarter-38.49%
Perf Half Y-63.03%
Perf YTD-64.47%
Perf Year-64.12%
Perf 3Y-95.22%
Perf 5Y-99.99%
Perf 10Y-100.00%
Recom-
Target Price7.75
Prev Close0.38
Price0.37
Change %-2.43%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Aug 31, 2021InitiatedCCantor FitzgeraldOverweight$22+5,910.9%
May 18, 2021InitiatedHH.C. WainwrightBuy$23+6,184.2%
Sep 11, 2020InitiatedBBTIG ResearchBuy
Jul 12, 2019UpgradeWWBB SecuritiesBuy → Strong Buy
Mar 12, 2019UpgradeWWBB SecuritiesSpeculative Buy → Buy
Jan 26, 2018InitiatedNNomuraBuy$18+4,818.0%
Oct 06, 2017InitiatedSSeaport Global SecuritiesBuy$19+5,091.3%
Oct 04, 2017ReiteratedHH.C. WainwrightBuy$33 → $36+9,736.1%
Feb 24, 2017ReiteratedFFBR & Co.Outperform$36 → $25+6,730.6%
Jul 27, 2016ReiteratedFFBR CapitalOutperform$33 → $36+9,736.1%

Peers

Mkt cap
TickerCompanyMkt cap
IRWDIronwood Pharmaceuticals Inc806.23M
AYTUAytu BioPharma Inc19.67M
CPIXCumberland Pharmaceuticals Inc91.70M
SCYXScynexis Inc33.99M
BFRIBiofrontera Inc13.92M
TLPHTalphera Inc54.50M
TXMDTherapeuticsMD Inc21.41M
KMDAKamada Ltd469.02M
APUSApimeds Pharmaceuticals US Inc3.56M
SBFMSunshine Biopharma Inc2.09M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Raday GileadChief Operating OfficerOct 01 '26Sale0.0014,310,0001,431176,910,000Oct 06 07:00 AM
Raday GileadChief Operating OfficerJul 10 '26Sale0.0014,130,0001,413218,780,000Jul 13 04:03 PM
Raday GileadChief Operating OfficerApr 06 '26Sale0.0015,740,0001,574261,060,000Apr 22 06:09 PM

News

latest 14 of 200
  • Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate (PR Newswire) +13.87%
  • $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma (PR Newswire)
  • Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet (PR Newswire)
  • RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results (PR Newswire)
  • RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota and Clenpiq (FinanceWire)
  • RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities (PR Newswire) +36.16%
  • Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development (PR Newswire)
  • RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement (PR Newswire) +10.24%
  • RedHill Biopharma Announces Up To $19.4 Million Private Placement (PR Newswire)
  • RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation (PR Newswire) -21.56%
  • RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo (PR Newswire)
  • RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak (PR Newswire)
  • RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms (PR Newswire)
  • RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024S12024-08-290.000--2.57--
2023S12023-08-171.000--5.40--
2023Q12023-06-12-1.250-510.973.60--
2021S22022-02-17-500-330-22.0724.08-
2021S12021-08-26-600-118-21.5025.02-
2020S22021-03-18-700-242.5-21.4626.03-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2013FY-1,700-1,670-1,7000.010.00
2014FY-1,300-1,310-1,3007.017.01
2015FY-1,878-1,808-1,8990.000.03
2016FY-2,284-2,180-2,4080.100.00
2017FY-2,582-2,783-2,6184.003.90
2018FY-1,700-1,779-1,6748.369.55
2019FY-1,400-1,338-1,4296.296.88
2020FY-2,078-1,778-2,10664.3868.13
2021FY-2,100-2,033-2,10285.7687.90
2022FY-3.000--1,15361.80-
2023FY0.250-92.0626.53-
2024FY0.000--1.7008.04-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-2618.421-1673.545-1429.41-2105.773-2102.254-1152.77292.062-6.732-0.101
Period201720182019202020212022202320242025
EPS, quarterly-459.24-490.439-327.01-203.372-555.058-39.905510.972
PeriodQ3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23
Sales, annual4.0358.3336.31164.81185.81661.5586.51300.288
Period201720182019202020212022202320242025
Sales, quarterly21.7122.17218.27618.10317.41912.7683.565
PeriodQ3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23
Shares, annual0.0210.0280.0350.0380.0520.0930.7871.295.092
Period201720182019202020212022202320242025
Shares, quarterly0.0470.0520.0530.0580.0640.0930.097
PeriodQ3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.290.006.5161.5685.8264.816.318.33
Cost of Goods Sold Incl. D&A0.14-0.623.4533.2149.4437.152.272.83
Gross Profit-0.14--0.623.0628.3536.3827.664.055.51
Selling, General and Administrative Excl. Other3.367.855.8834.4171.03117.5791.7947.3944.71
Research and Development0.972.041.603.527.2529.5216.6117.4824.78
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-3.50-7.97-6.51-31.35-42.68-81.19-64.13-43.34-39.20
Interest Expense1.620.350.040.430.480.460.710.440.00
Unusual Expense0.00-1.29-8.27-21.53-13.370.00-0.09-0.82-0.40
Net Income Before Taxes-5.10-8.110.3623.85-71.39-97.81-76.71-42.44-38.69
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-5.76-8.140.3623.85-71.39-97.81-76.71-42.44-38.69
Net Income From Continuing Operations-5.76-8.140.3623.85-71.39-97.81-76.71-42.44-38.69
Net Income-6.14-0.43-8.3123.85-71.39-97.81-76.71-42.44-38.69
EPS (Recurring)-1.01-0.42-11.4433.91-1,303.85-2,102.24-2,107.57-1,448.71-1,685.62
EPS (Basic, Before Extraordinaries)-1.01-0.10-6.7392.06-1,152.77-2,102.25-2,105.77-1,429.41-1,673.54
EPS (Diluted)-1.01-0.10-6.7392.06-1,152.77-2,102.25-2,105.77-1,429.41-1,673.54
EBITDA-3.36-7.56-5.88-29.37-34.55-63.03-55.32-42.12-39.11
Non-Operating Income (Expense)0.02-1.08-1.3634.11-41.60-16.16-11.960.520.11
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.460.671.645.6510.224.233.042.67
Price To Sales Ratio-11.290.951.450.141.404.5428.5615.40
Gross Margin---47.0346.0642.3942.6864.0966.06
Operating Margin--2,765.38--481.35-69.33-94.61-98.95-686.71-470.47
Net Margin--150.00-366.25-115.97-113.98-118.36-672.45-464.35
Shares Outstanding6.085.091.290.790.090.050.040.040.03
Market Capitalization3.253.257.925.768.99135.20310.26214.09157.45

Income statement, quarterly

Currency USD, millions
Metric2026S12025S1
Total Revenue0.004.11
Cost of Goods Sold Incl. D&A0.141.62
Gross Profit-0.142.49
Selling, General and Administrative Excl. Other3.366.90
Research and Development0.970.97
Other Operating Expense0.000.00
Operating Income-3.50-4.41
Interest Expense1.621.10
Unusual Expense0.000.00
Net Income Before Taxes-5.10-4.17
Income Taxes0.000.00
Consolidated Net Income-5.76-4.17
Net Income From Continuing Operations-5.76-4.17
Net Income-6.14-4.17
EPS (Recurring)-1.01-2.31
EPS (Basic, Before Extraordinaries)-1.01-2.32
EPS (Diluted)-1.01-2.32
EBITDA-3.36-4.24
Non-Operating Income (Expense)0.021.35
Gross Margin-60.60
Operating Margin--107.33
Net Margin--101.32
Shares Outstanding6.082.29
Market Capitalization3.254.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.974.626.3635.9838.0029.7947.8753.1846.21
Short Term Receivables1.702.873.2935.3532.5229.341.641.392.26
Inventories0.003.735.7012.0415.449.073.292.093.08
Other Current Assets0.860.690.802.523.182.300.410.120.13
Total Current Assets6.5311.9116.1485.9089.1570.5053.2156.7951.68
Net Property, Plant & Equipment1.110.441.187.194.225.703.810.160.23
Total Investments and Advances12.220.150.150.1516.1716.160.150.140.15
Long-Term Note Receivable0.200.00-------
Intangible Assets5.295.555.5865.6371.6587.8816.935.325.29
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets25.3418.0423.05158.87181.19180.2474.1062.4157.34
Short Term Debt Incl. Current Port. of LT Debt0.170.350.72116.251.621.710.830.000.00
Accounts Payable0.731.173.284.2311.6611.554.183.324.81
Other Current Liabilities18.3220.7015.2576.9868.1959.975.607.067.03
Total Current Liabilities19.2222.2219.24197.4681.4773.2410.6210.3811.83
Long Term Debt0.900.000.466.4486.2085.192.980.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities0.960.501.283.374.657.950.500.840.45
Total Liabilities21.0822.7320.98207.27172.32166.3814.1011.2212.28
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity4.27-4.682.07-48.408.8813.8660.0051.1945.07
Total Shareholders Equity4.27-4.682.07-48.408.8813.8660.0051.1945.07
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity4.27-4.682.07-48.408.8813.8660.0051.1945.07
Total Liabilities & Stockholders Equity25.3418.0423.05158.87181.19180.2474.1062.4157.34
Book Value Per Share0.84-3.632.63-519.34169.37361.061,701.241,804.302,118.44
Tangible Book Value Per Share-0.20-7.93-4.46-1,223.52-1,197.86-1,927.571,221.311,616.771,870.00
Full-Time Employees131153123211193-7594
Price to Book Ratio-2.060.281.66-0.2015.2322.383.573.082.60
Return on Assets-37.541.7626.23-41.99-54.12-60.32-62.18-64.62-69.77
Return on Equity-----860.29-207.69-76.34-80.40-85.17
Return on Invested Capital-8.37-945.10--102.88-77.44-67.38-75.60-101.78
Quick Ratio0.340.370.540.370.900.844.705.274.11
Current Ratio0.340.540.840.441.090.965.015.474.37

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-6.14-0.43-8.3123.85-71.39-97.81-76.71-42.44-38.69
Depreciation0.140.410.621.988.1218.168.811.220.09
Other Funds (Non Cash)2.48-7.72-3.79-45.9926.2215.7110.502.692.84
Funds from Operations-3.52-7.74-11.48-20.15-37.05-63.94-57.40-38.54-35.76
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.07-1.982.06-15.587.98-1.158.48-2.351.41
Cash from Operating Activities-4.59-9.73-9.41-35.73-29.07-65.09-48.92-40.88-34.35
Capital Expenditures-0.01-0.01-0.01-0.01-0.20-0.12-54.15-0.20-0.06
Net Assets From Acquisitions0.000.000.000.000.000.00-0.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00-0.00-
Purchase or Sale of Investments0.391.710.000.018.47-8.0318.255.385.39
Purchase of Investments0.00-0.310.000.000.00-8.510.00-6.41-6.95
Sale Or Maturity of Investments0.392.020.000.018.470.4818.2511.8012.35
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00-0.00-
Cash from Investing Activities0.371.70-0.010.008.27-8.15-35.905.185.33
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.507.838.3013.9223.7182.6024.0936.4242.13
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.507.838.3013.9223.7182.6024.0936.4242.13
Proceedsfrom Stock Options0.000.000.0013.9223.7178.5924.0336.4241.77
Issuance or Reduction of Debt, Net0.000.000.000.000.000.0078.610.000.00
Change in Long Term Debt0.000.000.000.000.000.0078.610.000.00
Issuance of Long Term Debt0.000.000.000.000.000.0078.610.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.000.00
Net Financing Active Other Cash Flow0.000.000.798.63-10.84-7.40-16.110.00-0.50
Other Financing Activities Uses0.000.000.00-6.54-10.84-7.40-20.140.00-0.50
Cash from Financing Activities5.427.388.4621.3811.4173.5184.9635.6241.63
Exchange Rate Effect-0.00-0.000.01-0.02-0.08-0.100.130.09-0.10
Net Change in Cash1.20-0.65-0.96-14.36-9.470.180.270.0212.51
Free Cash Flow-4.61-9.73-9.42-35.74-29.27-65.21-49.33-41.05-34.37
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S1
Cash & Short Term Investments5.163.03
Short Term Receivables0.005.35
Inventories0.003.17
Other Current Assets3.411.01
Total Current Assets8.5712.56
Net Property, Plant & Equipment0.980.29
Total Investments and Advances11.220.00
Intangible Assets5.295.53
Other Assets0.000.00
Total Assets26.2718.38
Short Term Debt Incl. Current Port. of LT Debt0.220.21
Accounts Payable0.580.84
Other Current Liabilities24.7621.24
Total Current Liabilities25.5622.29
Long Term Debt0.860.00
Other Liabilities0.930.50
Total Liabilities27.3522.79
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value0.000.00
Common Equity-1.08-4.41
Total Shareholders Equity-1.08-4.41
Accumulated Minority Interest0.000.00
Total Equity-1.08-4.41
Total Liabilities & Stockholders Equity26.2718.38
Book Value Per Share-0.18-1.93
Tangible Book Value Per Share-1.05-4.34
Price to Book Ratio-2.060.09
Quick Ratio0.340.42
Current Ratio0.340.56

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S1
Net Income-6.14-4.17
Depreciation0.140.17
Other Funds (Non Cash)2.48-0.43
Funds from Operations-3.52-4.43
Extraordinary Item0.000.00
Changes in Working Capital-1.07-0.63
Cash from Operating Activities-4.59-5.05
Capital Expenditures-0.01-0.00
Net Assets From Acquisitions0.000.00
Sale of Fixed Assets and Businesses0.000.00
Purchase or Sale of Investments0.390.00
Purchase of Investments0.000.00
Sale Or Maturity of Investments0.390.00
Other Uses0.000.00
Other Sources0.000.00
Cash from Investing Activities0.37-0.00
Cash Dividends Paid0.000.00
Preferred Dividends (Cash Flow)0.000.00
Change in Capital Stock5.503.48
Repurchase of Common Pref Stock0.000.00
Sale of Common Pref Stock5.503.48
Proceedsfrom Stock Options0.000.00
Issuance or Reduction of Debt, Net0.000.00
Change in Long Term Debt0.000.00
Issuance of Long Term Debt0.000.00
Reduction of Long Term Debt0.00-
Net Financing Active Other Cash Flow0.000.00
Other Financing Activities Uses0.000.00
Cash from Financing Activities5.423.28
Exchange Rate Effect-0.000.01
Net Change in Cash1.20-1.76
Free Cash Flow-4.61-5.06

Revenue breakdown

Pharmaceutical Preparations2024: 8.04M 2025: 286.00K
Israel2024: 8.04M 2025: 286.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.77%0.1M7.9M2.04M
2026-10-151.62%0.1M7.9M2.03M
2026-09-303.90%0.2M5.4M1.80M
2026-09-154.35%0.2M5.4M1.83M
2026-08-310.15%0.0M5.4M1.81M
2026-08-140.27%0.0M5.4M211.20K
2026-07-310.55%0.0M5.4M215.59K
2026-07-150.37%0.0M5.4M221.22K
2026-06-300.58%0.0M5.4M207.25K
2026-06-150.31%0.0M4.6M184.70K
2026-05-290.48%0.0M4.6M56.93K
2026-05-150.47%0.0M4.6M42.72K
2026-04-300.41%0.0M4.6M39.32K
2026-04-150.16%0.0M4.5M42.28K
2026-03-310.43%0.0M4.5M471.67K
2026-03-130.42%0.0M4.5M486.08K
2026-02-270.63%0.0M4.5M483.58K
2026-02-130.73%0.0M4.5M486.89K
2026-01-301.38%0.1M4.5M959.81K
2026-01-153.87%0.2M4.5M1.35M

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-21SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-13424B5SEC
2026-10-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-07SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-07SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-07-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-07-14424B3SEC
2026-07-13EFFECTEffectiveness filing by commission orderSEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-02F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-07-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-29424B5SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-06-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-18SEC
2026-06-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-09SEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-08SEC
2026-06-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-02SEC
2026-05-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.43K1
2026-090000
2026-080000
2026-07001.41K1
2026-060000
2026-050000
2026-04001.57K1
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Yorkville Advisors Global, LP2.35%
GAGNON SECURITIES LLC1.45%
CITADEL ADVISORS LLC1.26%
Lido Advisors, LLC0.21%
CITIGROUP INC0.21%
RHUMBLINE ADVISERS0.20%
UBS Group AG0.08%
Federation des caisses Desjardins du Quebec0.07%
ROYAL BANK OF CANADA0.01%
GAMMA Investing LLC0.00%

Funds

Fund% owned
-

OakChart. RDHL. Cached 15 minutes.